Your browser doesn't support javascript.
loading
PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk.
Nikolic, Dragana; Castellino, Giuseppa; Banach, Maciej; Toth, Peter P; Ivanova, Ekaterina; Orekhov, Alexander N; Montalto, Giuseppe; Rizzo, Manfredi.
Afiliación
  • Nikolic D; Biomedical Department of Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.
  • Castellino G; Euro-Mediterranean Institute of Science and Technology, Palermo, Italy.
  • Banach M; Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Lodz, Poland.
  • Toth PP; CGH Medical Center, Sterling, Illinois, USA; University of Illinois, School of Medicine, Peoria, Illinois; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.
  • Ivanova E; Department of Development and Regeneration, Group of Biomedical Sciences, KU Leuven, Leuven, Belgium.
  • Orekhov AN; Laboratory of Angiopathology, Institute for Atherosclerosis Research (Skolkovo), Moscow, Russian Federation.
  • Montalto G; Consiglio Nazionale delle Ricerche, Istituto di Biomedicina e Immunologia Molecolare, Italy.
  • Rizzo M; Biomedical Department of Internal Medicine and Medical Specialties, University of Palermo, Via del Vespro, 141, 90127, Palermo, Italy.
Curr Pharm Des ; 23(6): 894-902, 2017 03 26.
Article en En | MEDLINE | ID: mdl-27719644
Peroxisome proliferator-activated receptors (PPAR) are implicated in the pathology of several metabolic diseases including obesity, diabetes, and atherosclerosis. PPAR agonists exert multiple lipid modifying actions which are beneficial to the prevention of atherosclerosis. Such benefits in lipid lowering actions include improvements in atherogenic dyslipidemia that seems to be particularly expressed in individuals at higher cardiovascular (CV) risk. In addition, the favorable effects of PPAR agonists on different cardio-metabolic parameters are established in several metabolic conditions, such as diabetes mellitus, insulin resistance, and heightened systemic inflammation. The goal of this review is to summarize the current evidence on PPAR agonists and their effects on atherogenic dyslipidemia and CV risk. The main findings indicate that PPAR agonists improve not only the lipid profile, but also lipoprotein subfractions associated with atherogenic dyslipidemia and other CV markers. However, future prospective studies are required to establish the long-term effects of such therapies on atherogenic lipoproteins and their benefit on CV outcomes.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Receptores Activados del Proliferador del Peroxisoma / Aterosclerosis / Dislipidemias / Hipolipemiantes Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies / Systematic_reviews Límite: Animals / Humans Idioma: En Revista: Curr Pharm Des Asunto de la revista: FARMACIA Año: 2017 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Emiratos Árabes Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Receptores Activados del Proliferador del Peroxisoma / Aterosclerosis / Dislipidemias / Hipolipemiantes Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies / Systematic_reviews Límite: Animals / Humans Idioma: En Revista: Curr Pharm Des Asunto de la revista: FARMACIA Año: 2017 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Emiratos Árabes Unidos